Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671483 · ClinicalTrials.gov registry record · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
A Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,088
- Enrollment target
- 20
- Study locations
NCT06671483: Recruiting Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.
NCT06671483 is a Phase 3 study of Psoriatic Arthritis that is actively recruiting participants, run by Takeda. The registered enrollment target is 1,088 participants, above the 830-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06671483, a Phase 3 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,088 participants
- Enrollment target
- 20
- Study locations
Study Summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Primary Outcome
ACR responses are the numerical measurement of improvement in multiple disease assessment criteria. It is a composite clinical outcome assessment (COA) measure that includes both clinician-reported outcome assessments (ClinROs) and patient-reported outcomes (PROs). An ACR20 response is defined as: greater than or equal to (\>=) 20 percent (%) improvement from baseline in both swollen joint count 66 joints (SJC66) and tender joint count 68 joints (TJC68), and \>=20% improvement from baseline in 3
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zasocitinib
- DRUG Active Comparator
Study Locations (20)
Florida
- Arthritis & Rheumatic Disease Specialties (AARDS) - Aventura
- RASF- Clinical Research Center - Boca Raton
- Clinical Research of West Florida | Clearwater, FL - Clearwater
- GNP Research, LLC | Hollywood, FL - Cooper City
- Driven Research LLC - Coral Gables
- Tectum Medical Research - Davie
- Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research - Hialeah
- Bioresearch Partners - Miami
- HMD Research LLC - Orlando
California
- First OC Dermatology Research Inc. - Fountain Valley
- Purushotham & Akther Kotha MD - La Mesa
- Triwest Research Associates LLC - La Mesa
- The Cohen Medical Centers - Thousand Oaks
- Foothill Arthritis Clinic - Tujunga
- Medvin Clinical Research - Whittier
Arizona
- AARR- Chandler AZ - Chandler
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Phoenix
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Phoenix
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Phoenix
Colorado
- Denver Arthritis Clinic | Denver, CO - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,088 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2028-01-28 |
| Phase | Phase 3 |
What NCT06671483 shows while recruiting
NCT06671483 is an interventional study that assigns participants to a tested intervention. Its 1,088 participants enrollment target places it among the larger protocols in the corpus, above the 830-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (31% higher).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06671483 names 20 study sites across 4 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06671483 about?
NCT06671483 is a clinical study titled "A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines". Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modif...
What is the current status of trial NCT06671483?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,088 participants. The study started on 2025-03-03. Estimated completion is 2028-01-28.
What conditions does trial NCT06671483 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT06671483?
The interventions under investigation include: Placebo (DRUG), Zasocitinib (DRUG), Active Comparator (DRUG).
Who is sponsoring clinical trial NCT06671483?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671483 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06671483's enrollment target sits among peer trials
1,088 6th of 48 higher than 43 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06585241 · 1,094 participants · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI